Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DURGA-5: AZD0120 consolidation versus continuous standard therapy in transplant-ineligible newly diagnosed multiple myeloma
2025-524014-29-00Phase 3Authorised
- Sponsor
- AstraZeneca
- Start
- Sep 2026
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Countries
- 16
01
Overview
Phase 3, randomised, open-label trial of GC012 in multiple myeloma (MM) (2 arms), sponsored by AstraZeneca. Primary endpoints: Progression-free survival and MRD-negative complete response rate at 9 months. Planned start Sep 2026; status: authorised.
02
Drugs
GC012
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on 2025-524014-29-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-524014-29-00.